$65.56
0[0.00%]
Last update: 4:00PM Get Real Time Here
Intra-Cellular Therapies
(NASDAQ:ITCI)Latest News for Intra-Cellular Therapies Stock (NASDAQ:ITCI)
Intra-Cellular Therapies Stock (NASDAQ: ITCI)
Categories: All
Wednesday, May 08, 2024
Tuesday, May 07, 2024
- Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $90 Price TargetBenzinga Newsdesk - 3 days ago
- Intra-cellular Therapies Reiterates Full Year 2024 Caplyta Net Product Sales Guidance Of $645M-$675MBenzinga Newsdesk - 3 days ago
- Intra-Cellular Therapies Q1 2024 GAAP EPS $(0.16) Beats $(0.32) Estimate, Sales $144.866M Beat $141.381M EstimateBenzinga Newsdesk - 3 days ago
Wednesday, April 24, 2024
Tuesday, April 23, 2024
Monday, April 22, 2024
- Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90Benzinga Newsdesk - Apr 22, 2024, 12:44PM
- The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 ExpertsBenzinga Insights - Apr 22, 2024, 9:00AM
- Mizuho Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $96Benzinga Newsdesk - Apr 22, 2024, 7:11AM
Friday, April 19, 2024
Thursday, April 18, 2024
Wednesday, April 17, 2024
- Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Raises Price Target to $77Benzinga Newsdesk - Apr 17, 2024, 11:31AM
- B of A Securities Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $91Benzinga Newsdesk - Apr 17, 2024, 7:59AM
- Baird Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $103Benzinga Newsdesk - Apr 17, 2024, 7:35AM
- TD Cowen Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90Benzinga Newsdesk - Apr 17, 2024, 6:15AM
- Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into WednesdayAvi Kapoor - Apr 17, 2024, 2:06AM
Tuesday, April 16, 2024
- Intra-Cellular Therapies Announces $500M Proposed Public Offering Of Common StockBenzinga Newsdesk - Apr 16, 2024, 4:13PM
- Intra-Cellular Therapies Inc Files For Mixed Shelf Offering, Size Not DisclosedBenzinga Newsdesk - Apr 16, 2024, 4:06PM
- Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Apr 16, 2024, 2:17PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Apr 16, 2024, 12:31PM
- Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment StudyVandana Singh - Apr 16, 2024, 12:13PM
- UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - Apr 16, 2024, 10:15AM
- Intra-Cellular shares are trading higher after the company announced Lumateperone 42 mg once daily as adjunctive therapy to antidepressants met its primary endpoint.Benzinga Newsdesk - Apr 16, 2024, 8:56AM
- Market-Moving news for April 16thBenzinga Newsdesk - Apr 16, 2024, 8:36AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Apr 16, 2024, 8:07AM
- Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $82 Price TargetBenzinga Newsdesk - Apr 16, 2024, 8:00AM
- Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga Newsdesk - Apr 16, 2024, 7:25AM
- Intra-Cellular Reports Phase 3 Topline Results From Study 501 Evaluating Lumateperone As Adjunctive Therapy In Patients With Major Depressive Disorder; Lumateperone 42 Mg Met The Primary EndpointBenzinga Newsdesk - Apr 16, 2024, 7:03AM
- Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News PendingBenzinga Newsdesk - Apr 16, 2024, 6:55AM
Friday, April 05, 2024
Thursday, April 04, 2024
Wednesday, April 03, 2024
Friday, February 23, 2024
- Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $101 Price TargetBenzinga Newsdesk - Feb 23, 2024, 12:13PM
- RBC Capital Reiterates Outperform on Intra-Cellular Therapies, Maintains $86 Price TargetBenzinga Newsdesk - Feb 23, 2024, 11:17AM
- Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Lowers Price Target to $100Benzinga Newsdesk - Feb 23, 2024, 9:51AM
- Where Intra-Cellular Therapies Stands With AnalystsBenzinga Insights - Feb 23, 2024, 7:00AM
- Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $82Benzinga Newsdesk - Feb 23, 2024, 6:46AM
Thursday, February 22, 2024
- Intra-Cellular Therapies Sees 2024 CAPLYTA Net Product Sales $645M-$675MBenzinga Newsdesk - Feb 22, 2024, 7:32AM
- Intra-Cellular Therapies Q4 2023 GAAP EPS $(0.30) Beats $(0.45) Estimate, Total Revenues $132.10M Miss $135.67M EstimateBenzinga Newsdesk - Feb 22, 2024, 7:31AM
- Earnings Scheduled For February 22, 2024Benzinga Insights - Feb 22, 2024, 5:27AM